Abstract: The present disclosure pertains to compositions comprising anti-VEGF proteins and methods for producing such compositions.

Abstract: The present disclosure pertains to compositions comprising anti-VEGF proteins and methods for producing such compositions.

Abstract: The present disclosure pertains to compositions comprising anti-VEGF proteins and methods for producing such compositions.

Abstract: The present disclosure pertains to compositions comprising anti-VEGF proteins and methods for producing such compositions.

Abstract: The present disclosure pertains to compositions comprising anti-VEGF proteins and methods for producing such compositions.

Abstract: The present invention provides an improved process for the preparation of halogenated benzylamine having the formula I from halogenated benzonitriles, Formula I wherein, X1 is selected from group consisting of hydrogen, chloro or fluoro, provided at least one X1 is chloro or fluoro.

Abstract: The present disclosure pertains to compositions comprising anti-VEGF proteins and methods for producing such compositions.

Abstract: The present disclosure pertains to compositions comprising anti-VEGF proteins and methods for producing such compositions.

Abstract: Automated systems and methods for implementing and managing the submission, quote, proposal and binding stages (i.e., placement process) for securing insurance coverage.

Abstract: Systems and method for producing a small-scale mixer are provided. In some implementations, a method for includes obtaining dimensions of an at-scale mixer. The method also includes determining first dimensions of the small-scale mixer based on respective dimensions of the at-scale mixer. The method further includes determining second dimensions of the small-scale mixer independent of the dimensions of the at-scale mixer. Additionally, the method includes generating the small-scale mixer using the first dimensions and the second dimensions using a three-dimensional printer.

Abstract: The present disclosure pertains to compositions comprising anti-VEGF proteins and methods for producing such compositions.

Abstract: The present invention relates to a synthesis of novel Zn(II)-based Metal Organic Frameworks having mixed organic ligands of 1,3,5-benzene tricarboxylic acid (BTC) and 2-methylimidazole (mIm) through a simple and economic solvothermal method. The synthesized MOFs has cuboids morphology having high surface area (1248 m2/g) capable of hydrogen adsorption at ?10° C. to 25° C. temperature and 100 bar pressure. The hydrogen adsorption capabilities of the novel MOFs are in the range of 23-0.2 weight percent.

Abstract: The invention relates to immunogenic compositions comprising a capsular polysaccharide (CP) from Streptococcus agalactiae, commonly referred to as group B streptococcus (GBS), conjugated to a carrier protein, and optionally including an aluminum-based adjuvant. The invention further relates to methods for inducing an immune response in subjects against GBS and/or for reducing or preventing invasive GBS disease in subjects using the compositions disclosed herein. The resulting antibodies can be used to treat or prevent GBS infection via passive immunotherapy.

Abstract: The present disclosure pertains to compositions comprising anti-VEGF proteins and methods for producing such compositions.

Abstract: The present invention relates to an apparatus and method for bio-assisted treatment of spent caustic obtained from hydrocarbon and gas processing installations. The present invention also relates to method for recovery of caustic and recovery of sulfur from spent caustic. According to present invention, the sulfide removal is about 96% and the sulphur formation and deposition on the electrode lies in range of 72±8%.

Abstract: The invention relates to immunogenic compositions comprising a capsular polysaccharide (CP) from Streptococcus agalactiae, commonly referred to as group B Streptococcus (GBS), conjugated to a carrier protein, and optionally including an aluminum-based adjuvant. The invention further relates to methods for inducing an immune response in subjects against GBS and/or for reducing or preventing invasive GBS disease in subjects using the compositions disclosed herein. The resulting antibodies can be used to treat or prevent GBS infection via passive immunotherapy.

Abstract: A radio node that selectively performs a remedial action is described. During operation, the radio node detects a potential change in a location of the radio node relative to a predefined location. For example, the radio node may detect the potential change in the location based at least in part on a change in a network parameter of the radio node and/or by performing a scan of wireless signals in an environment of the radio node. Then, in response to detecting the potential change in the location, the radio node determines the location of the radio node (e.g., by using a positioning system). When there is at least a predefined change in the location of the radio node relative to the predefined location, the radio node selectively performs the remedial action. Notably, the remedial action may include: providing an alert or a notification, discontinuing transmissions, or re-register the radio node.

Abstract: The present disclosure pertains to compositions comprising anti-VEGF proteins and methods for producing such compositions.

Abstract: The invention relates to immunogenic polysaccharide-protein conjugates comprising a capsular polysaccharide (CP) from Streptococcus agalactiae, commonly referred to as group B. streptococcus (GBS), and a carrier protein, wherein the CP is selected from the group consisting of serotypes Ia, Ib, II, III, IV, V, VI, VII, VIII, and IX, and wherein the CP has a sialic acid level of greater than about 60%. The invention also relates to methods of making the conjugates and immunogenic compositions comprising the conjugates. The invention also relates to immunogenic compositions comprising polysaccharide-protein conjugates, wherein the conjugates comprise a CP from GBS serotype IV and at least one additional serotype. The invention further relates to methods for inducing an immune response in subjects against GBS and/or for reducing or preventing invasive GBS disease in subjects using the compositions disclosed herein. The resulting antibodies can be used to treat or prevent GBS infection via passive immunotherapy.

Abstract: Methods for configuring a cellular telecommunication network are disclosed. A radio frequency (RF) configuration of a selected base station is adjusted to a predetermined setting. A baseline signature is determined based on a plurality of key performance indicators (KPIs). A characteristic of the RF configuration is changed to an updated setting. An updated signature is determined based on measurements of the KPIs after the characteristic is adjusted. The baseline signature and updated signature are analyzed to determine a composite difference profile based on the adjusted characteristic. It is determined that the composite difference profile represents a net improvement in performance of the cellular communication network based on one or more criteria and the adjusted characteristic is maintained as part of a new baseline configuration.